egfr mutation positive tumors: treatment strategies in front line and at relapse
Published 7 years ago • 8.9K plays • Length 23:10Download video MP4
Download video MP3
Similar videos
-
18:06
egfr inhibitors in mutation ( ) patients: current therapeutic strategies in the frontline setting
-
20:24
targeted treatment with egfr tkis: front line options
-
10:06
debate: what is the optimal timing for egfr-targeted therapy? - favor frontline therapy
-
20:07
acquired egfr resistance: what are the current therapeutic strategies?
-
53:55
advancing care for patients with egfr mutation–positive nsclc: precision medicine strategies
-
37:23
nsclc: integrating egfr-inhibiting therapies into clinical pathways for first-line treatment
-
20:18
understanding, preventing, and delaying egfr resistance in the era of osimertinib
-
17:27
how, when, and where to utilize erlotinib, afatinib, and gefitinib in egfr positive nsclc
-
19:28
managing t790-positive egfr-mutated nsclc
-
19:53
managing progression in egfr-mutant nsclc patients: potential impact of 2nd and 3rd generation tkis?
-
44:03
egfr: the challenge of primary and secondary resistance
-
33:52
keynote lecture: targeted therapies in lung cancer 2.0 – advances and promises
-
14:30
adjuvant therapy for egfr mutant nsclc
-
21:35
long term management of egfr-mutant nsclc -tsao
-
10:45
debate: adjuvant egfr-directed therapy for patients with early stage nsclc? - no
-
1:56
what targeted therapies are used for people with the egfr mutation?
-
1:25
current treatment recommendations and future directions for egfr-mutant nsclc
-
1:41
egfr mutations in patients with lung cancer
-
6:28
sequential treatment with afatinib and osimertinib in patients with egfr mutation-positive nsclc